Vizianagaram, India

Krishnamurthy Toppaladoddi

This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Shilpa Medicare Limited. Active years: 2020.

USPTO Granted Patents = 2 

% Patents Active = 50.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2020

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Krishnamurthy Toppaladoddi

Introduction

Krishnamurthy Toppaladoddi is a notable inventor based in Vizianagaram, India. He has made significant contributions to the field of pharmaceuticals, holding 2 patents that showcase his innovative spirit and dedication to improving medical formulations.

Latest Patents

His latest patents include "Stable melphalan liquid injectable formulations," which relates to a stable, non-aqueous liquid formulation consisting essentially of melphalan or a pharmaceutical acceptable salt thereof. This formulation is free of antioxidants, organic acids, and added chloride ions, and it includes solvents such as dimethyl acetamide and polyethylene glycol. Another significant patent is for "Pharmaceutical compositions of lenvatinib," which comprises lenvatinib mesylate and a stabilizer, selected from calcium hydroxide and potassium hydroxide, in a specific weight percentage.

Career Highlights

Krishnamurthy Toppaladoddi is currently associated with Shilpa Medicare Limited, where he continues to work on innovative pharmaceutical solutions. His expertise in developing stable formulations has positioned him as a valuable asset in the pharmaceutical industry.

Collaborations

He collaborates with talented coworkers such as Shivakumar Pradeep and Guptha Chinni Guru Deva, contributing to a dynamic and innovative work environment.

Conclusion

Krishnamurthy Toppaladoddi's contributions to pharmaceutical innovations reflect his commitment to enhancing medical treatments through his inventive work. His patents are a testament to his expertise and dedication to the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…